The House of Lords Science and Technology Committee continues taking evidence for its inquiry into Life Sciences and the Industrial Strategy. Over three evidence sessions the Committee questions representatives from NHS Foundation Trusts, industry bodies and various scientific academies.
Purpose of sessions
The Committee questions three NHS Foundation Trusts on how the NHS can get better at stimulating, and benefitting from, innovation and the structures needed to make sure this takes place.
In the second evidence session the Committee hears from representative industry bodies and the Association of Medical Research Charities (AMRC). They give their views on why some pharmaceutical companies have moved research and development out of the UK and the effect Brexit will have on the science and innovation in the UK.
In the final evidence session, the Committee questions representatives of scientific academies on how the strategy should be implemented.
Tuesday 24 October in Committee Room 4A, Palace of Westminster
- Keith Chantler, Director of Innovation, Central Manchester University Hospitals NHS Foundation Trust
- Dame Julie Moore, Chief Executive, University Hospitals Birmingham NHS Foundation Trust
- Professor Bryan Williams, Director of Research, University College London Hospitals NHS Foundation Trust
- Mike Thompson, Chief Executive Officer, Association of the British Pharmaceutical Industry (ABPI)
- Nisha Tailor, Head of Policy and Public Affairs, Association of Medical Research Charities (AMRC)
- Steve Bates OBE, Chief Executive Officer, BioIndustry Association (BIA)
- Professor Sir Robert Lechler, President, Academy of Medical Sciences (AMS)
- Professor Joyce Tait, Director of the Innogen Institute at University of Edinburgh, Royal Society of Edinburgh
- Professor Mark Tooley, President of the Institute of Physics and Engineering in Medicine (IPEM), Royal Academy of Engineering (RAEng)
Topics likely to be covered across the sessions include:
- Whether NHS budgets allow for the adoption on innovations and if there should be financial incentives to encourage this
- If the NHS is ready for the level of innovation detailed in the strategy
- How the life sciences strategy can be implemented, and who should be accountable
- Opportunities for policy change post-Brexit